A phase 2, multicenter study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (LN-144) for the treatment of patients with metastatic melanoma.
Sarnaik A, Curti B, Davar D, Kirkwood J, Hamid O, Lutzky J, Wilson M, Kluger H, Whitman E, Phan G, Thomas S, Lewis K, Arkenau H, Chesney J, Larsen B, Gorbatchevsky I, Suzuki S, Samberg N, Fardis M. A phase 2, multicenter study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (LN-144) for the treatment of patients with metastatic melanoma. Journal Of Clinical Oncology 2018, 36: tps9595-tps9595. DOI: 10.1200/jco.2018.36.15_suppl.tps9595.Peer-Reviewed Original ResearchAutologous tumor-infiltrating lymphocytesTumor-infiltrating lymphocytesTreatment of patientsMulticenter studyMetastatic melanomaPhase 2PatientsLymphocytesMelanoma